Leadership Team

Stéphane Bancel has been Moderna's Chief Executive Officer since October 2011 and has served on Moderna’s board of directors since March 2011. Prior to joining Moderna, Mr. Bancel was the Chief Executive Officer of the French diagnostics company bioMérieux SA for five years. From July 2000 to March 2006, he held various positions at Eli Lilly and Company, including Managing Director, Belgium, and Executive Director, Global Manufacturing Strategy and Supply Chain. Before his tenure at Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.

In addition to his role at Moderna, Mr. Bancel is a board member of Generate:Biomedicines and Indigo, and a Venture Partner at Flagship Pioneering. He holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.

Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and member of the US National Academy of Engineering in 2024.

Stephen Hoge serves as the President of Moderna and leads all Research & Development for the company. Since Moderna’s early days, Dr. Hoge has led our scientific efforts, including the creation of our platform and therapeutic areas. More recently, he has assumed responsibility for the company’s Clinical Development Office. He joined Moderna in late 2012 from McKinsey & Company, where he was a partner in the healthcare practice. Prior to McKinsey, Dr. Hoge was a resident physician in New York City. He holds an M.D. with thesis from the University of California, San Francisco, and a B.S. in neuroscience from Amherst College. Currently, Dr. Hoge also serves on the Board of Directors of Axcella Health, Inc., a publicly traded, clinical-stage biotechnology company.

As Chief Technical Operations and Quality Officer, Dr. Collins is responsible for the technical development, quality, and supply of preclinical, clinical and commercial programs within Moderna’s portfolio. Dr. Collins joined Moderna from Novartis, where he held roles of increasing responsibility over the last nearly 30 years, focused on pharmaceutical production and manufacturing, including roles serving as Head of Global Chemical Operations and Anti-Infectives and as Head of Global Chemical Operations. Dr. Collins received his Bachelor of Science in Chemistry and his Ph.D. in Organic Chemistry from University College Cork, Ireland. He also conducted post-doctoral cancer research at Arizona State University.

As Chief Brand Officer, Kate Cronin is responsible for amplifying Moderna’s story and the promise of mRNA science for patients. Ms. Cronin joined Moderna from Ogilvy Health, part of WPP plc., where she served as Global CEO. In this role, she led the full spectrum of Ogilvy Health’s core capabilities including public relations and influence, brand strategy, advertising, medical education, market access, and patient and consumer engagement. Additionally, Ms. Cronin grew Ogilvy’s business in the health and wellness arena, encompassing a broad portfolio including pharmaceuticals, consumer health, insurance, hospitals, health technology and medical devices. Ms. Cronin led integrated campaigns involving social, digital, brand and public relations for Ogilvy’s largest, long-term health clients including BMS, Boehringer Ingelheim, Merck and Pfizer. Prior to her role as CEO, Ms. Cronin held numerous leadership roles within Ogilvy including Global Managing Director, Managing Director of Ogilvy Public Relations’ New York office, and most recently Co-President of Ogilvy Health in the United States. Before her 17-year tenure at Ogilvy, Ms. Cronin was a Partner at Porter Novelli. Before starting her career in communications, Ms. Cronin conducted research in the field of neurobiology at Cornell University Medical College. She coauthored several research articles focused on learning and memory and published in peer-review publications. Ms. Cronin received a Bachelor of Arts in biology from Smith College.

As Chief People and Digital Technology Officer, Tracey Franklin leads Moderna’s talent and digital organizations.

Before taking on her expanded role, Ms. Franklin served as Chief Human Resources Officer of Moderna from 2019 to 2024, leading the Company’s people strategy, culture and workforce capabilities to support rapid growth and innovation through the COVID-19 pandemic. Under her leadership, Moderna expanded its workforce from approximately 800 to nearly 6,000 employees globally.

She joined Moderna following 15 years at Merck & Co., Inc. where she most led Merck’s global talent strategy as Vice President, HR Chief Talent and Strategy Officer and served on Merck’s HR Leadership Team. Ms. Franklin’s previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the U.K. and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Merck’s global footprint. She was based in Switzerland, the U.K. and the U.S.

Ms. Franklin holds a Bachelor of Arts in communication arts and sciences from Pennsylvania State University and a Master of Arts in industrial and organizational psychology from Fairleigh Dickinson University.

As chief legal officer and corporate secretary, Shannon Thyme Klinger leads Moderna’s legal, governance and corporate compliance efforts. Ms. Klinger joined Moderna from Novartis (NYSE: NVS), where she served as Chief Legal Officer and a member of the Novartis Executive Committee since 2018. Previously, she served as Chief Ethics, Risk & Compliance Officer. During her ten-year tenure at Novartis, she held other roles of increasing responsibility, including as Chief Ethics and Compliance Officer and Global Head of Litigation, General Counsel and Global Head of Legal at Sandoz, a Novartis division. Across her career, Ms. Klinger’s work has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, championing the responsible use of data, and enabling excellence in product launches. She is also a committed advocate for diversity, equity and inclusion. Ms. Klinger served on the board of directors of the SIX Group in Switzerland from 2016 to 2020. Ms. Klinger received her Juris Doctorate with honors from the University of North Carolina at Chapel Hill and a bachelor’s degree in psychology from the University of Notre Dame. She is a member of the State Bar of Georgia and the District of Columbia Bar.

As Chief Medical Officer, Jacqueline Miller, M.D., leads Moderna's development organization.

Dr. Miller, a pediatrician with two decades in vaccine development, joined Moderna in 2020 as the Therapeutic Area Head for Infectious Diseases. In this role, she led efforts to develop and refine Moderna’s portfolio of vaccines against a range of infectious diseases. Prior to Moderna, she served as Head of Clinical R&D at GlaxoSmithKline’s U.S. R&D Center. Throughout her career, Dr. Miller has supported seven novel vaccine licensures for populations ranging from infants to older adults, including Moderna’s Spikevax and mRESVIA.

Dr. Miller earned her Doctor of Medicine degree from Northwestern University’s Feinberg School of Medicine and completed her pediatric training at the Children’s Hospital of Philadelphia.

As EVP of Research, Rose Loughlin, Ph.D., leads Moderna's platform science and therapeutics research organization, focusing on pioneering scientific advancements and further strengthening the Company’s innovative pipeline. 

Dr. Loughlin previously served as Senior Vice President of Research and Early Development at Moderna, where she played a crucial role in advancing the Company's portfolio and platform strategy since joining in 2016. Before joining Moderna, Dr. Loughlin held roles at Biogen in business development and at L.E.K. Consulting, where she contributed to defining corporate and portfolio growth strategies for biopharmaceutical companies. Dr. Loughlin holds a Ph.D. in Biophysics from the University of California, Berkeley, and a Bachelor of Arts in physics from Harvard University.

As Chief Financial Officer, Jamey Mock oversees financial, business development and business services functions at Moderna. Mr. Mock previously served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas. Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University.

Dr. Noubar Afeyan is the co-founder and chairman of Moderna and the founder and CEO of Flagship Pioneering, a company that creates bioplatform companies to transform human health and sustainability. An entrepreneur and biochemical engineer, Noubar holds more than 100 patents and has co-founded more than 70 life science and technology startups during his 36-year career. Noubar entered biotechnology during its emergence as an academic field and industry, completing his doctoral work in biochemical engineering at MIT in 1987. He was a senior lecturer at MIT’s Sloan School of Management from 2000 to 2016, a lecturer at Harvard Business School until 2020, and he currently serves as a member of the MIT Corporation. He teaches and speaks around the world on topics ranging from entrepreneurship, innovation, and economic development to biological engineering, new medicines, and renewable energy. In 2022, Noubar was elected to the National Academy of Engineering. Noubar has received multiple awards for his passionate advocacy of the contributions of immigrants to economic and scientific progress. He is the co-founder of the Aurora Prize for Awakening Humanity and a number of other philanthropic projects.

Stéphane Bancel has been Moderna's Chief Executive Officer since October 2011 and has served on Moderna’s board of directors since March 2011. Prior to joining Moderna, Mr. Bancel was the Chief Executive Officer of the French diagnostics company bioMérieux SA for five years. From July 2000 to March 2006, he held various positions at Eli Lilly and Company, including Managing Director, Belgium, and Executive Director, Global Manufacturing Strategy and Supply Chain. Before his tenure at Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.

In addition to his role at Moderna, Mr. Bancel is a board member of Generate:Biomedicines and Indigo, and a Venture Partner at Flagship Pioneering. He holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.

Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and member of the US National Academy of Engineering in 2024.

Sandra Horning, M.D., FACP, FASCO, is an academic and industry veteran, currently a co-founder and advisor for EQRx, a biotechnology company focused on creating innovative medicines at lower prices. Dr. Horning previously served as Chief Medical Officer and Head of Global Product Development at Genentech/Roche (SIX: RO, ROG; OTCQX: RHHBY) from 2014 to 2019. Over the course of a decade in industry, she oversaw the approval of 15 new medicines across a variety of diseases, including cancer, multiple sclerosis, influenza and blindness. Prior to joining Genentech, Dr. Horning was a Professor of Medicine, Oncology and Blood and Bone Marrow Transplantation at Stanford University for more than 20 years, where she remains an Emerita Professor. Dr. Horning currently serves on the Board of Directors of Gilead Sciences, Inc. (Nasdaq: GILD). She has received numerous awards and recognitions throughout her career – she is the recipient of the Healthcare Businesswomen’s Association 2020 Woman of the Year, 2017 Duane Roth Memorial Award, 2014 Fierce Biotech Top Women in Biotech Award and 2010 Top Women in Bay Area Business Award. She was President of the American Society of Clinical Oncology from 2005-2006, has served on the editorial boards of multiple peer-reviewed medical journals, including Journal of Clinical Oncology, Clinical Cancer Research, Clinical Lymphoma, Leukemia & Lymphoma, the Annals of Internal Medicine and the American Journal of Medicine, and has authored more than 300 publications. Dr. Horning received her M.D. from University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University.

Mr. Hussain most recently served as Chief Executive Officer of Vifor Pharma from 2021 to 2023. Prior to that, he served in various leadership roles at GlaxoSmithKline, most recently as global president, pharmaceuticals & vaccines. Earlier in his career, Mr. Hussain held various global leadership roles at Eli Lilly and Company.

Mr. Hussain currently holds various non-executive director and advisory roles, including as the Chairman of Asceneuron SA, director for Mallinckrodt Pharmaceuticals and Alfasigma SpA and as an advisor to 4Bio Capital. He previously served on the boards of Cochlear Limited, CSL, Teva Pharmaceutical and Immunocore.

Mr. Hussain holds a BSc from the Loughborough Institute of Technology.

Betsy Nabel, M.D., brings a unique perspective to health care based on her experience as a physician, research scientist, academic medicine leader, and wellness advocate. Through February 2021, Dr. Nabel was President of Brigham Health, which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization, a position she held from 2010. Simultaneous with her service as President of Brigham Health, Dr. Nabel was also a Professor of Medicine at Harvard Medical School from 2010 to 2021. Prior to joining Brigham Health, she held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. On March 1, 2021, Dr. Nabel became the Executive Vice President for Strategy at ModeX Therapeutics, a new biotechnology company focused on developing innovative immunotherapies for cancer and viral diseases. Her colleagues have elected her to the American Academy of the Arts and Sciences, the National Academy of Medicine, the Association of American Physicians, the American Society of Clinical Investigation, and she is a Fellow of the American Association for the Advancement of Science. A native of St. Paul, Minnesota, Dr. Nabel attended Weill Cornell Medical College and completed her internal medicine and cardiology training at Brigham and Women’s Hospital.

François Nader, M.D. is an experienced biopharmaceutical executive and director with broad expertise across development, regulatory affairs and commercial. Dr. Nader served as President, Chief Executive Officer and Executive Director of NPS Pharmaceuticals from 2008 until 2015, when the company was acquired by Shire (now part of Takeda (NYSE: TAK)). During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. Prior to NPS, Dr. Nader was a venture partner at Care Capital, a venture capital firm. He previously served on Aventis Pharma’s North America Leadership Team, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. Dr. Nader previously led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc (now part of Sanofi (NASDAQ: SNY)). In addition to serving on the Moderna board of directors, Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma (NASDAQ: XLRN), Prevail Therapeutics (NASDAQ: PRVL) and Talaris Therapeutics. He also serves on the Board of Directors of Alexion Pharmaceuticals (NASDAQ: ALXN) and advisor for SVB-Leerink. Dr. Nader is the past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharma (NASDAQ: NPSP), Advanced Accelerator Applications (NASDAQ: AAAP), Baxalta (NYSE: BXLT), Clementia Pharmaceuticals (NASDAQ: CMTA), Trevena (NASDAQ: TRVN) and Noven (NASDAQ: NOVN). In 2013, he was recognized as the Ernst and Young National Life Science Entrepreneur of the Year. Dr. Nader earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee.

David M. Rubenstein is Co-Founder and Co-Chairman of the Board of The Carlyle Group. Previously, Mr. Rubenstein served as Co-Chief Executive Officer of Carlyle. Mr. Rubenstein is also the Chairman, Chief Executive Officer, and principal owner of the Baltimore Orioles of Major League Baseball. He is the host of two interview shows on Bloomberg TV and is the New York Times bestselling author of The American Story, How to Lead, The American Experiment, How to Invest, and The Highest Calling. Prior to forming Carlyle in 1987, Mr. Rubenstein practiced law in Washington, D.C. and from 1977 to 1981 was Deputy Assistant for Domestic Policy to President Jimmy Carter.

Among other philanthropic endeavors, Mr. Rubenstein is Chairman of the Boards of the John F. Kennedy Center for the Performing Arts, the Council on Foreign Relations, the National Gallery of Art, the Economic Club of Washington, and the University of Chicago and serves on the Boards of Memorial Sloan-Kettering Cancer Center, Johns Hopkins Medicine, the Institute for Advanced Study, the Brookings Institution, the American Academy of Arts and Sciences, and the World Economic Forum. Mr. Rubenstein serves as Chairman of the Harvard Global Advisory Council and the Madison Council of the Library of Congress. 

Mr. Rubenstein is a magna cum laude graduate of Duke University, where he was elected Phi Beta Kappa. Following Duke, Mr. Rubenstein graduated from the University of Chicago Law School, where he was an editor of the Law Review. 

Paul Sagan is a senior advisor to and an Executive in Resident (XIR) at General Catalyst, a the venture capital firm, where he focuses on investments in internet software, services, and infrastructure companies. He was previously a Managing Director at the firm, with responsibility for helping to build the firm’s growth equity investing practice. Prior to joining General Catalyst, Mr. Sagan was CEO of Akamai Technologies, a pioneer in internet content delivery, application performance and cloud security, and now one of the largest cloud services providers. He joined Akamai in October 1998 as chief operating officer, became president the following year, and was CEO from April 2005 until 2013. Mr. Sagan was elected to the Akamai Board of Directors in January 2005 and served until 2019. Mr. Sagan is also a director of VMware, Inc. Previously, he served as a director of iRobot Corp, as well as Catalina Labs (acquired by Asurion), Dow Jones & Company (acquired by News Corp.), Digitas, Inc. (acquired by Publicis Group), EMC Corp. (acquired by Dell Technologies), and Maven Networks (acquired by Yahoo!). Mr. Sagan began his career as a television journalist and his work was recognized with three Emmy Awards for broadcast news in New York City. Later he joined Time Warner to co-found three businesses: NY1, the 24-hour cable news network; Roadrunner, the world’s first consumer broadband service; and Pathfinder, one of the first internet advertising platforms. President Obama appointed Mr. Sagan to the President's National Security Telecommunications Advisory Committee in 2010 and he served until 2017. He has been a fellow of the American Academy of Arts and Sciences since 2008, and in 2009 was named Ernst & Young’s Entrepreneur of the Year in the technology category. In 1996 the World Economic Forum named Mr. Sagan a Global Leader for Tomorrow. Mr. Sagan is a graduate of the Medill School of Journalism at Northwestern University, where he is a life trustee. He also serves as Chairman of the Board of Directors of ProPublica, and was appointed by Governor Charlie Baker to be Chairman of the Massachusetts Board of Elementary and Secondary Education from 2015 to 2019.

Elizabeth Tallett has spent more than 35 years in strategic leadership and operational roles in worldwide biopharmaceutical and consumer products industries, including as principal of Hunter Partners, President and CEO of Transcell Technologies Inc., President of Centocor Pharmaceuticals, and member of the Parke-Davis Executive Committee. In addition to serving on the Moderna Board of Directors, Ms. Tallett is currently the Chair of Elevance Health, Inc. (previously Anthem, Inc.) and she is a director of Qiagen, Inc. Ms. Tallett was a founding member of the Biotechnology Council of New Jersey and chairs the board of trustees at Solebury School in Pennsylvania. She was named a Financial Times Outstanding Director of the year in 2015 and recognized as one of the National Association of Corporate Directors (NACD) Directorship 100 honorees in 2019. She is a former director of Principal Financial Group, Meredith Group, Inc., Coventry Health Care, Inc., Varian, Inc., IntegraMed America Inc., and Varian SemiConductor Associates, Inc. Born and educated in England, Ms. Tallett graduated from Nottingham University with a dual first class honours degree in mathematics and economics.

Henri A. Termeer served as chairman, president, and chief executive officer of Genzyme Corporation for nearly three decades. Mr. Termeer was appointed president of Genzyme in 1983, two years after the company’s founding. He became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer was active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. Mr. Termeer was a board member of Massachusetts Institute of Technology Corporation and served on its executive committee, a director of Massachusetts General Hospital, board member of Partners HealthCare, a member of the Board of Fellows of Harvard Medical School, and on the board of the Biotechnology Industry Organization (BIO). He also served on the boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., and Medical Simulation Corporation. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors and was a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. Mr. Termeer was also chairman emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. He was elected a fellow of the American Academy of Arts and Sciences in 1999. Mr. Termeer was chairman of the Federal Reserve Bank of Boston’s board of directors from 2010-2011 and served on the board of directors of the Pharmaceutical Research and Manufacturers of America. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an MBA from the Darden School at the University of Virginia. Mr. Termeer has been recognized by several highly regarded organizations for his contributions to the health care and entrepreneurial fields.